KUALA LUMPUR: iNix Technologies Holdings Bhd has submitted its application for registration with Malaysian National Pharmaceutical Regulatory Agency (NPRA) pursuant to its earlier agreements to source Covid-19 vaccines from China.
The company said its wholly-owned iNix Network Sdn Bhd had submitted the application to NPRA on January 12.
iNix's suppliers for the Covid-19 vaccines are Sinovac Biotech Co Ltd, Cansino Biologics Inc and Sinopharm China National Biotech Group Co Ltd (CNBG).
"iNix's registration with NPRA is essential for the distribution of vaccines in Malaysia.
"This evaluation process is made by the Product Evaluation Committee of NPRA and drugs control authority for approval before the Covid-19 vaccine can be used in Malaysia," it said.
Yesterday, Prime Minister Tan Sri Muhyiddin Yassin reportedly said to achieve group immunity, as much as 60 per cent to 70 per cent or 20 to 23 million Malaysians needed to be administered the Covid-19 vaccine.
Muhyiddin said for now, the government had signed a preliminary agreement with Covax facilities, Pfizer and AstraZeneca for the procurement of the Covid-19 vaccines to secure the supply of vaccine for about 40 per cent of the population.
"The government is also in the final stage of negotiations with Sinovac, Cansino and Gamaleya to obtain a guaranteed vaccine supply for 80 per cent of the total population of the country or 26.5 million," he said.
iNix said when it had received the approval from NPRA, it would be able to import the vaccines and supply to the Health Ministry to conduct a third phase clinical trial.
The trial would be fully sponsored by iNix as a CSR (corporate social responsibility) initiative, it added.
"This first clinical trial in Malaysia is expected to involve about 3,000 volunteers," it said.